CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Huei-sheng Vincent Chen |
Basic Biology II |
Endothelial cells and ion channel maturation of human stem cell-derived cardiomyocytes |
$1,587,610 |
| University of California, Irvine |
Dr. Aileen J Anderson |
Basic Biology II |
Role of the microenvironment in human iPS and NSC fate and tumorigenesis |
$1,256,194 |
| Stanford University |
Dr. Steven Edward Artandi |
Basic Biology II |
Self-renewal and senescence in iPS cells derived from patients with a stem cell disease |
$931,285 |
| Salk Institute for Biological Studies |
Ronald Mark Evans |
Basic Biology II |
Molecular Characterization and Functional Exploration of Nuclear Receptors in hiPSCs |
$1,712,880 |
| Calimmune, Inc. |
Geoff Symonds |
Disease Team Research I |
GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE |
$8,278,722 |
| Stanford University |
Dr. Gary Steinberg |
Disease Team Research I |
Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke |
$17,244,851 |
| University of California, San Diego |
Dr. Lawrence S. B. Goldstein |
Disease Team Research I |
Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis |
$5,694,308 |
| University of California, Los Angeles |
Dr. Donald B. Kohn |
Disease Team Research I |
Stem Cell Gene Therapy for Sickle Cell Disease |
$8,833,695 |
| University of California, Los Angeles |
Dr. Irvin SY Chen |
Disease Team Research I |
HPSC based therapy for HIV disease using RNAi to CCR5. |
$9,905,604 |
| ViaCyte, Inc. |
Allan Robins |
Disease Team Research I |
Cell Therapy for Diabetes |
$0 |
| Cedars-Sinai Medical Center |
Eduardo Marbán |
Disease Team Research I |
Autologous cardiac-derived cells for advanced ischemic cardiomyopathy |
$5,560,232 |
| University of California, San Francisco |
Dr. Mitchel S Berger |
Disease Team Research I |
Stem Cell-Mediated Oncocidal Gene Therapy of Glioblastoma (GBM) |
$6,214,914 |
| City of Hope, Beckman Research Institute |
Prof. Karen S Aboody M.D. |
Disease Team Research I |
Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials |
$17,890,623 |
| Stanford University |
Dr. Alfred T Lane |
Disease Team Research I |
iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa |
$11,039,208 |
| Stanford University |
Professor Irving L Weissman MD |
Disease Team Research I |
Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells |
$18,759,276 |
| University of California, Los Angeles |
Dr. Dennis J Slamon |
Disease Team Research I |
Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors |
$19,979,660 |
| City of Hope, Beckman Research Institute |
Prof. John A. Zaia |
Disease Team Research I |
ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS |
$14,536,969 |
| University of Southern California |
Mark Salman Humayun |
Disease Team Research I |
Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) |
$18,904,916 |
| University of California, San Diego |
Dr. Dennis A Carson |
Disease Team Research I |
Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) |
$19,999,826 |
| University of California, San Diego |
Dr. Gene Wei-Ming Yeo |
Basic Biology I |
RNA Binding Protein-mediated Post-transcriptional Networks Regulating HPSC Pluripotency |
$1,308,901 |
| University of California, San Diego |
Karl H. Willert |
Basic Biology I |
WNT signaling and the control of cell fate decisions in human pluripotent stem cells. |
$1,329,298 |
| University of California, Davis |
Dr. Min Zhao |
Basic Biology I |
Directing migration of human stem cells with electric fields |
$816,228 |
| University of California, Los Angeles |
Dr. Michael A. Teitell |
Basic Biology I |
Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer |
$1,323,029 |
| University of Southern California |
Dr. Martin Pera |
Basic Biology I |
The stem cell microenvironment in the maintenance of pluripotency and reprogramming |
$1,325,723 |
| Stanford University |
Dr. Julien Sage |
Basic Biology I |
The retinoblastoma (RB) gene family in cellular reprogramming |
$1,357,085 |
| Stanford University |
Dr. Susan K McConnell |
Basic Biology I |
Identification and characterization of human ES-derived DA neuronal subtypes |
$1,404,853 |
| University of California, Los Angeles |
Bennett G Novitch |
Basic Biology I |
Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons |
$1,228,278 |
| University of California, Los Angeles |
Dr. Robb Maclellan Dr. |
Basic Biology I |
Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate |
$917,667 |
| University of Southern California |
Dr. Wange Lu |
Basic Biology I |
Defining the molecular mechanisms of somatic cell reprogramming |
$1,365,580 |
| Stanford University |
Professor Helen M. Blau PhD |
Basic Biology I |
Molecular Mechanisms of Reprogramming towards Pluripotency |
$1,408,332 |
| University of California, Los Angeles |
Dr. Luisa Iruela-Arispe |
Basic Biology I |
Molecular Characterization and Functional Exploration of Hemogenic Endothelium |
$1,371,477 |
| Stanford University |
Dr. Theo D. Palmer PhD |
Research Training II |
Stanford CIRM Training Program |
$7,017,629 |
| University of California, San Diego |
Dr Sylvia Evans |
Research Training II |
Interdisciplinary Stem Cell Training Program at UCSD II |
$7,432,600 |
| Children’s Hospital of Los Angeles |
Dr. David Warburton |
Research Training II |
CHLA Stem Cell Training Grant |
$5,020,920 |
| University of California, Los Angeles |
Kenneth Dorshkind |
Research Training II |
UCLA CIRM Research Training Program II |
$7,790,488 |
| Scripps Research Institute |
Dr. Ulrich Mueller |
Research Training II |
Training Stem Cell Researchers at the Chemistry-Biology Interface |
$3,697,326 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr Alessandra Sacco |
Research Training II |
Type III CIRM Stem Cell Research Training Program |
$2,781,376 |
| Gladstone Institutes, J. David |
Dr. Robert W Mahley |
Research Training II |
Gladstone CIRM Scholars Program |
$4,869,300 |
| Buck Institute for Age Research |
Dr. Xianmin Zeng |
Research Training II |
CIRM Research Training Program in Stem Cells and Aging |
$1,472,416 |
| University of California, Davis |
Dr. Frederick J Meyers MD |
Research Training II |
UC Davis Stem Cell Training Program |
$4,838,291 |
| University of California, Santa Barbara |
Dr. Dennis O. Clegg |
Research Training II |
Training Program in Stem Cell Biology and Engineering |
$2,448,823 |
| University of California, San Francisco |
Dr. Susan J Fisher PhD |
Research Training II |
Training Program in Stem Cell Research at UCSF |
$7,814,027 |
| University of California, Berkeley |
Ellen Robey |
Research Training II |
Interdisciplinary Training in Stem Cell Biology, Engineering and Medicine |
$6,888,557 |
| University of Southern California |
Dr. Robert E Maxson |
Research Training II |
CIRM Stem Cell Biology Training Program |
$5,827,817 |
| Salk Institute for Biological Studies |
Juan Carlos Izpisua Belmonte |
Research Training II |
Training in the Biology of Human Embryonic Stem Cells and Emerging Technologies II |
$2,886,221 |
| University of California, Santa Cruz |
Dr. David Haussler |
Research Training II |
UCSC CIRM Training Program in Systems Biology of Stem cells |
$4,397,002 |
| University of California, Irvine |
Dr. Peter John Donovan Dr. |
Research Training II |
UCI-CIRM Research Training Program II |
$6,067,550 |
| City of Hope, Beckman Research Institute |
Dr. Michael E. Barish Ph, D. |
Research Training II |
City of Hope Research Training Program in Stem Cell Biology |
$2,197,782 |
| Geron Corporation |
Dr. Jane Stephanie Lebkowski Dr. |
Targeted Clinical Development |
Evaluation of Safety and Preliminary Efficacy of Escalating Doses of GRNOPC1 in Subacute Spinal Cord Injury |
$0 |
| City of Hope, Beckman Research Institute |
Dr. Jiing-Kuan Yee Ph.D. |
Basic Biology III |
Use of human iPS cells to study spinal muscular atrophy |
$1,268,868 |
